Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Epacadostat (formerly INCB024360; IDO-IN-1; INCB-024360; INCB-24360; INCB24360) is an orally bioavailable, potent and selective IDO1 (indoleamine-(2,3)-dioxygenase) inhibitor with potential immunomodulating and antitumor activity. In inhibits IDO1 with an IC50 of 10 nM. By inhibiting IDO1 in tumor cells. Epacadostat increases and restores the proliferation and activation of various immune cells such as dendritic cells, NK cells, T-cells. Epacadostat was under investigation in a phase 3 clinical trial. But according to the results presented at the 2018 ASCO Annual Meeting, in patients with unresectable or metastatic melanoma, adding epacadostat to pembrolizumab (Keytruda) did not result in greater clinical benefit over pembrolizumab alone, according to data from the phase III ECHO-301/KEYNOTE-252 study.
Targets |
IDO1 (IC50 = 71.8 nM)
|
||
---|---|---|---|
ln Vitro |
Epacadostat (INCB 024360) has no effect on other related enzymes like IDO2 or tryptophan 2,3-dioxygenase (TDO), but it specifically inhibits human IDO1 in cellular experiments with an IC50 value of about 10 nM. In a comparable test utilizing mouse IDO1-transfected HEK293/MSR cells, epacadostat (INCB 024360) also shown considerable action against mouse IDO1, with an IC50 value of 52.4 nM±15.7 nM [1].
|
||
ln Vivo |
For a period of 12 days, female Balb/c mice with CT26 tumors were given an oral dose of 100 mg/kg of epacadostat twice a day. Kynurenine is potently inhibited in plasma, tumors, and lymph nodes by epacadostat (INCB 024360). 50 mg/kg Epacadostat (INCB 024360) decreased plasma kynurenine levels in naive C57BL/6 mice in less than an hour, and these levels stayed at least 50% suppressed for the duration of an 8-hour period[2].
|
||
Enzyme Assay |
IDO Enzyme Assay [4].
Human IDO with an N-terminal His tag was expressed in E.coli and purified to homogeneity. IDO catalyzes the oxidative cleavage of the pyrrole ring of the indole nucleus of tryptophan to yield N’-formylkynurenine. The assays were performed at room temperature as described in the literature using 20 nM IDO and 2 mM D-Trp in the presence of 20 mM ascorbate, 3.5 µM methylene blue and 0.2 mg/mL catalase in 50 mM potassium phosphate buffer (pH 6.5). The initial reaction rates were recorded by continuously following the absorbance increase at 321 nm due to the formation of N’-formlylkynurenine. In order to determine mode of inhibition, Km and Vmax values were determined for D-Trp at several inhibitor concentrations. Ki values were determined using the following equation which describes the behavior of a competitive inhibitor. No effect on Vmax was observed, but Km was linearly related to the inhibitor concentration. This profile is indicative of competitive inhibition. Ki values were determined by linear regression of the following equation: Km,eff = Km (1 + [I]/Ki). See the following reference for more details on the determination of binding kinetics of ligands to IDO via absorption spectroscopy and Soret peak analyses, Sono, M., Taniguchi, T., Watanabe, Y., and Hayaishi, O. Indoleamine 2,3-Dioxygenase; Equilibrium Studies of the Tryptophan Binding to the Ferric, Ferrous and Co-bound Enzymes. J. Biol. Chem. (1980), 255, 1339-1345. Mode of Inhibition - Binding Kinetics.[4] For mode of inhibition analysis, the final D-Trp concentrations varied between 0.6 mM and 30 mM. The initial reaction rates of these reactions were fit to the Michaelis-Mention equation by nonlinear regression analysis (Graphpad Prism). A competitive Ki was determined by linear regression of a plot of Km vs. [inhibitor], such that Ki = -(x-intercept). For example compound 1 was determined to be a competitive inhibitor of IDO with respect to the substrate D-trp, as shown in Figure 1. |
||
Cell Assay |
Cell Based Determinations of Tryptophan and Kynurenine[2]
Both CT26 and PAN02 cells were plated at 3 × 105 cells/well in 6-well plates, and allowed to adhere overnight. The next day, the media were replaced, and appropriate wells received recombinant murine IFNγ to a final concentration of 100 ng/mL, whereas an unstimulated control received diluent. At that time, cells received IDO inhibitors across a 10-point dilution scheme. After 48 h, media were collected and centrifuged to remove dead cells and stored at −20°C until liquid chromotography/mass spectrometry (LC/MS) analysis as described below for tissue and plasma samples in the Pharmacodynamic Analyses section. Cell-based IDO and TDO assays[5] The HeLa cell–based kyn assay to determine inhibitory activity of INCB024360 was performed as described previously.27 For the DC-based kyn assay, DCs were differentiated from human monocytes (see “Lymphocyte and DC or HeLa cocultures” for details), and stimulated with 50 ng/mL human recombinant IFN-γ and 5 μg/mL lipopolysaccharide (LPS) from Salmonella typhimurium in complete RPMI 1640 for 2 days. Established and primary AML cells were also stimulated with 50 ng/mL human recombinant IFN-γ and 5 μg/mL LPS before kyn measurement. The determination of INCB024360 activity was performed similarly to the HeLa cell assay.[5] To determine INCB024360 activity against IDO in recombinant cells, HEK293/MSR cells were transiently transfected with full-length human or mouse IDO1, or mouse IDO2 cDNA, with Transit-293 transfection reagent or Lipofectamine 2000 reagents. INCB024360 at different concentrations was added to the recovered transfected cells seeded at 2 × 104 cells per well in a 96-well plate (200 μL/well). The cells were incubated for 2 days, and kyn in the supernatants was measured as described in the HeLa cell assay. The tryptophan 2,3-dioxygenase (TDO) assay was performed similarly with HEK293/MSR cells transfected with a human TDO expression vector.[5] |
||
Animal Protocol |
|
||
References |
[1]. Liu X, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010 Apr 29;115(17):3520-30.
[2]. Koblish HK, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther. 2010 Feb;9(2):489-98. [3]. Fu R, et al. LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment. Br J Pharmacol. 2018 Jul;175(14):3034-3049. [4]. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem. 2009 Dec 10;52(23):7364-7. doi: 10.1021/jm900518f. [5]. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010 Apr 29;115(17):3520-30. |
||
Additional Infomation |
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
Epacadostat is an orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1), with potential immunomodulating and antineoplastic activities. Epacadostat targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, INCB024360 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), NK cells, and T-lymphocytes, as well as interferon (IFN) production, and a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and DCs. Indoleamine 2,3-dioxygenase-1 (IDO1; IDO) mediates oxidative cleavage of tryptophan, an amino acid essential for cell proliferation and survival. IDO1 inhibition is proposed to have therapeutic potential in immunodeficiency-associated abnormalities, including cancer. Here, we describe INCB024360, a novel IDO1 inhibitor, and investigate its roles in regulating various immune cells and therapeutic potential as an anticancer agent. In cellular assays, INCB024360 selectively inhibits human IDO1 with IC(50) values of approximately 10nM, demonstrating little activity against other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). In coculture systems of human allogeneic lymphocytes with dendritic cells (DCs) or tumor cells, INCB024360 inhibition of IDO1 promotes T and natural killer (NK)-cell growth, increases IFN-gamma production, and reduces conversion to regulatory T (T(reg))-like cells. IDO1 induction triggers DC apoptosis, whereas INCB024360 reverses this and increases the number of CD86(high) DCs, potentially representing a novel mechanism by which IDO1 inhibition activates T cells. Furthermore, IDO1 regulation differs in DCs versus tumor cells. Consistent with its effects in vitro, administration of INCB024360 to tumor-bearing mice significantly inhibits tumor growth in a lymphocyte-dependent manner. Analysis of plasma kynurenine/tryptophan levels in patients with cancer affirms that the IDO pathway is activated in multiple tumor types. Collectively, the data suggest that selective inhibition of IDO1 may represent an attractive cancer therapeutic strategy via up-regulation of cellular immunity.[1] Malignant tumors arise, in part, because the immune system does not adequately recognize and destroy them. Expression of indoleamine-2,3-dioxygenase (IDO; IDO1), a rate-limiting enzyme in the catabolism of tryptophan into kynurenine, contributes to this immune evasion. Here we describe the effects of systemic IDO inhibition using orally active hydroxyamidine small molecule inhibitors. A single dose of INCB023843 or INCB024360 results in efficient and durable suppression of Ido1 activity in the plasma of treated mice and dogs, the former to levels seen in Ido1-deficient mice. Hydroxyamidines potently suppress tryptophan metabolism in vitro in CT26 colon carcinoma and PAN02 pancreatic carcinoma cells and in vivo in tumors and their draining lymph nodes. Repeated administration of these IDO1 inhibitors impedes tumor growth in a dose- and lymphocyte-dependent fashion and is well tolerated in efficacy and preclinical toxicology studies. Substantiating the fundamental role of tumor cell-derived IDO expression, hydroxyamidines control the growth of IDO-expressing tumors in Ido1-deficient mice. These activities can be attributed, at least partially, to the increased immunoreactivity of lymphocytes found in tumors and their draining lymph nodes and to the reduction in tumor-associated regulatory T cells. INCB024360, a potent IDO1 inhibitor with desirable pharmaceutical properties, is poised to start clinical trials in cancer patients.[2] |
Molecular Formula |
C11H13BRFN7O4S
|
|
---|---|---|
Molecular Weight |
438.23
|
|
Exact Mass |
436.991699
|
|
Elemental Analysis |
C, 30.15; H, 2.99; Br, 18.23; F, 4.34; N, 22.37; O, 14.60; S, 7.32
|
|
CAS # |
1204669-58-8
|
|
Related CAS # |
1204669-58-8 (INCB024360); 914471-09-3 (INCB14943); 1204669-37-3 (INCB024360);
|
|
PubChem CID |
135564890
|
|
Appearance |
White to gray solid
|
|
Density |
2.0±0.1 g/cm3
|
|
Boiling Point |
672.3±65.0 °C at 760 mmHg
|
|
Flash Point |
360.4±34.3 °C
|
|
Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
|
Index of Refraction |
1.742
|
|
LogP |
0.8
|
|
tPSA |
176Ų
|
|
SMILES |
O=S(NCCNC1=NON=C1/C(NC2=CC=C(F)C(Br)=C2)=N/O)(N)=O
|
|
InChi Key |
FBKMWOJEPMPVTQ-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)
|
|
Chemical Name |
(Z)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-((2-(sulfamoylamino)ethyl)amino)-1,2,5-oxadiazole-3-carboximidamide
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.62 mg/mL (5.98 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.62 mg/mL (5.98 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (5.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (5.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 6: 10%DMSO+90%PEG400: 30mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2819 mL | 11.4095 mL | 22.8191 mL | |
5 mM | 0.4564 mL | 2.2819 mL | 4.5638 mL | |
10 mM | 0.2282 mL | 1.1410 mL | 2.2819 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03361865 | Completed Has Results | Drug: Pembrolizumab Drug: Epacadostat |
UC (Urothelial Cancer) | Incyte Corporation | December 4, 2017 | Phase 3 |
NCT03374488 | Completed Has Results | Drug: Pembrolizumab Drug: Epacadostat |
UC (Urothelial Cancer) | Incyte Corporation | December 22, 2017 | Phase 3 |
NCT03182894 | Withdrawn | Drug: Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA) |
Metastatic Colorectal Cancer | James J Lee | September 30, 2018 | Phase 1 Phase 2 |
NCT03516708 | Recruiting | Drug: Epacadostat Radiation: Short-course radiation |
Rectal Cancer | Washington University School of Medicine |
October 10, 2019 | Phase 1 Phase 2 |